Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Anaplastic Large Cell Lymphoma (ALCL)-Pipeline Review, H1 2015

Anaplastic Large Cell Lymphoma (ALCL)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Anaplastic Large Cell Lymphoma (ALCL)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Anaplastic Large Cell Lymphoma (ALCL)-Pipeline Review, H1 2015', provides an overview of the Anaplastic Large Cell Lymphoma (ALCL)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Anaplastic Large Cell Lymphoma (ALCL)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Anaplastic Large Cell Lymphoma (ALCL) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Anaplastic Large Cell Lymphoma (ALCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Anaplastic Large Cell Lymphoma (ALCL) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Anaplastic Large Cell Lymphoma (ALCL) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Anaplastic Large Cell Lymphoma (ALCL) Overview 7

Therapeutics Development 8

Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL)-Overview 8

Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL)-Comparative Analysis 9

Anaplastic Large Cell Lymphoma (ALCL)-Therapeutics under Development by Companies 10

Anaplastic Large Cell Lymphoma (ALCL)-Therapeutics under Investigation by Universities/Institutes 12

Anaplastic Large Cell Lymphoma (ALCL)-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Anaplastic Large Cell Lymphoma (ALCL)-Products under Development by Companies 16

Anaplastic Large Cell Lymphoma (ALCL)-Products under Investigation by Universities/Institutes 17

Anaplastic Large Cell Lymphoma (ALCL)-Companies Involved in Therapeutics Development 18

Akron Molecules AG 18

AstraZeneca PLC 19

Bayer AG 20

Celon Pharma Sp. z o.o. 21

Pfizer Inc. 22

Sareum Holdings plc 23

Seattle Genetics, Inc. 24

Sigma-Tau S.p.A. 25

Teva Pharmaceutical Industries Limited 26

Anaplastic Large Cell Lymphoma (ALCL)-Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

AKR-303-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

AZD-3463-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

brentuximab vedotin-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

CEP-28122-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

CEP-37440-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

copanlisib-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

crizotinib-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

KRA-0008-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

pegaspargase-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

SH-7129-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Small Molecules to Inhibit Aurora and ALK Kinase for Oncology-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Anaplastic Large Cell Lymphoma (ALCL)-Recent Pipeline Updates 58

Anaplastic Large Cell Lymphoma (ALCL)-Dormant Projects 78

Anaplastic Large Cell Lymphoma (ALCL)-Discontinued Products 79

Anaplastic Large Cell Lymphoma (ALCL)-Product Development Milestones 80

Featured News & Press Releases 80

Dec 07, 2014: Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting 80

Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting 81

Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 83

Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting 85

Sep 24, 2014: Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress 86

Apr 17, 2014: ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Available in Japan 88

Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma 88

Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma 89

Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma 91

Jun 01, 2013: Takeda Highlights Data From Phase I/II Clinical Trial Examining Use Of Adcetris in Pediatric Patients With Hodgkin Lymphoma Or Systemic Anaplastic Large Cell Lymphoma 93

Appendix 95

Methodology 95

Coverage 95

Secondary Research 95

Primary Research 95

Expert Panel Validation 95

Contact Us 95

Disclaimer 96

List of Tables

Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H1 2015 8

Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

Anaplastic Large Cell Lymphoma (ALCL)-Pipeline by Akron Molecules AG, H1 2015 18

Anaplastic Large Cell Lymphoma (ALCL)-Pipeline by AstraZeneca PLC, H1 2015 19

Anaplastic Large Cell Lymphoma (ALCL)-Pipeline by Bayer AG, H1 2015 20

Anaplastic Large Cell Lymphoma (ALCL)-Pipeline by Celon Pharma Sp. z o.o., H1 2015 21

Anaplastic Large Cell Lymphoma (ALCL)-Pipeline by Pfizer Inc., H1 2015 22

Anaplastic Large Cell Lymphoma (ALCL)-Pipeline by Sareum Holdings plc, H1 2015 23

Anaplastic Large Cell Lymphoma (ALCL)-Pipeline by Seattle Genetics, Inc., H1 2015 24

Anaplastic Large Cell Lymphoma (ALCL)-Pipeline by Sigma-Tau S.p.A., H1 2015 25

Anaplastic Large Cell Lymphoma (ALCL)-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 26

Assessment by Monotherapy Products, H1 2015 27

Number of Products by Stage and Target, H1 2015 29

Number of Products by Stage and Mechanism of Action, H1 2015 31

Number of Products by Stage and Route of Administration, H1 2015 33

Number of Products by Stage and Molecule Type, H1 2015 35

Anaplastic Large Cell Lymphoma (ALCL) Therapeutics-Recent Pipeline Updates, H1 2015 58

Anaplastic Large Cell Lymphoma (ALCL)-Dormant Projects, H1 2015 78

Anaplastic Large Cell Lymphoma (ALCL)-Discontinued Products, H1 2015 79

List of Figures

Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H1 2015 8

Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 27

Number of Products by Top 10 Targets, H1 2015 28

Number of Products by Stage and Top 10 Targets, H1 2015 28

Number of Products by Top 10 Mechanism of Actions, H1 2015 30

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 30

Number of Products by Top 10 Routes of Administration, H1 2015 32

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32

Number of Products by Top 10 Molecule Types, H1 2015 34

Number of Products by Stage and Top 10 Molecule Types, H1 2015 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Akron Molecules AG

AstraZeneca PLC

Bayer AG

Celon Pharma Sp. z o.o.

Pfizer Inc.

Sareum Holdings plc

Seattle Genetics, Inc.

Sigma-Tau S.p.A.

Teva Pharmaceutical Industries Limited

Anaplastic Large Cell Lymphoma (ALCL) Therapeutic Products under Development, Key Players in Anaplastic Large Cell Lymphoma (ALCL) Therapeutics, Anaplastic Large Cell Lymphoma (ALCL) Pipeline Overview, Anaplastic Large Cell Lymphoma (ALCL) Pipeline, Anaplastic Large Cell Lymphoma (ALCL) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com